What Clorom Treats: Main Uses and Benefits

Clorom, containing the active agent Clarithromycin, is commonly used in situations involving certain distressing symptoms related to bacterial infections across several key domains. Its use is focused on conditions caused by designated, susceptible bacteria.

---

Managing Acute and Specialized Infections

This medication is relevant in clinical settings that involve acute or unstable symptom patterns, particularly for upper and lower respiratory tract infections (like pneumonia, bronchitis flare-ups, and sinusitis), localized infections (such as otitis media and pharyngitis), and skin and soft tissue infections (like cellulitis). It is also relevant in specialized contexts for the management of the Mycobacterium avium complex (MAC) and for H. pylori eradication. The medication may assist with addressing symptoms that create noticeable physiological strain, such as fever, cough, and localized pain.

“Clorom provides supportive relief that helps ease the overall symptom load and contributes to improved comfort during symptomatic periods.”

In these scenarios, Clorom is applied in situations where symptoms may intensify temporarily, and may assist with maintaining functional stability.

---

Quick Fact: Support for Localized Pain Symptoms Clorom is commonly used to help with symptoms related to inflammatory or irritative states, such as pain and swelling, related to specific bacterial infections, like earaches caused by otitis media or the localized discomfort associated with pharyngitis and cellulitis.

Regulatory References

1. official DailyMed Prescribing Information

Official Eligibility Rules for Clorom

Clorom (Clarithromycin) is subject to strict eligibility rules based on governmental regulatory documents.

Populations for Whom Use is Contraindicated

• Patients with known hypersensitivity to Clarithromycin, Erythromycin, or any other macrolide antibacterial drug.
• Individuals with a history of cholestatic jaundice or hepatic dysfunction caused by previous Clarithromycin use.
• Patients with known QT prolongation (congenital or acquired) or a history of ventricular cardiac arrhythmia.
• Patients with uncorrected electrolyte disturbances such as hypokalemia or hypomagnesemia.
• Individuals suffering from severe hepatic failure in combination with renal impairment.

---

Age- and Condition-Based Restrictions

• Pediatric Use: The tablet formulation is not recommended for children younger than 12 years; use in infants under 6 months is not established for general infections.
• Organ Impairment: Patients with severe renal impairment (creatinine clearance < 30 mL/min) are eligible but must have their use restricted to a reduced dose and limited duration. Caution is also required for patients with impaired hepatic function.
• Pregnancy/Lactation: Use during pregnancy is not recommended unless no appropriate alternative therapy exists; use while breastfeeding may require the discontinuation of nursing.

Interactions with other medicines and products

Clorom, containing the active ingredient Clarithromycin, is officially classified as a strong inhibitor of the CYP3A4 enzyme and the P-glycoprotein transporter. This pharmacokinetic action is the basis for most documented interactions, resulting in increased systemic exposure of co-administered medicines.

Formally Contraindicated Combinations

Regulatory authorities strictly prohibit co-administration with certain substances due to the risk of life-threatening events:

• Agents associated with QT prolongation: Pimozide, Cisapride, Astemizole, Domperidone, and Terfenadine. Co-administration risks severe cardiac arrhythmias.
• Statins: Lovastatin and Simvastatin. Contraindicated due to the risk of markedly increased exposure leading to rhabdomyolysis.
• Ergot Alkaloids: Ergotamine and Dihydroergotamine. Contraindicated due to risk of acute ergot toxicity and vasospasm.

Exposure Modification and Risk Reinforcement

Clarithromycin increases the plasma concentrations of many drugs, including Digoxin, Carbamazepine, Theophylline, and Sildenafil. This exposure modification may require monitoring. Co-administration with other QT-prolonging medicines (e.g., Quinidine) increases the risk of QT prolongation.

For patients with pre-existing renal or hepatic impairment, co-administration of Colchicine is strictly prohibited according to regulatory labeling. Furthermore, strong CYP3A4 inducers like St. John’s wort may decrease Clarithromycin levels, potentially leading to sub-therapeutic concentrations.

Direct Blockade of Bacterial Protein Synthesis

Clarithromycin exerts its primary action by engaging the bacterial 50S ribosomal subunit, binding specifically and reversibly to the 23S ribosomal RNA. This interaction inhibits the bacterial translation pathway, physically obstructing the exit tunnel and halting the movement of nascent peptide chains. By immediately preventing the synthesis of proteins essential for cellular growth and division, the drug enforces a bacteriostatic effect, leading to a cessation of bacterial multiplication.

---

Causal Cascade and Systemic Delivery

The cessation of protein synthesis initiates a physiological cascade resulting in a reduction of the total pathogen burden. The overall effect is supported by the drug's ability to accumulate in host phagocytes (immune cells), facilitating targeted delivery to infection sites. The molecule's active metabolite, 14-(R)-hydroxyclarithromycin, shares the same ribosomal binding mechanism and contributes to the sustained systemic effect. The mechanism's functional activity is biologically constrained by Target-Site Modification of the 23S rRNA and bacterial Active Efflux pumps (e.g., Mef(A)) that reduce intracellular concentration.

How to Use Clorom

Clorom, which contains Clarithromycin, is administered through two officially approved routes: the oral route (tablets, extended-release tablets, and suspension) and as an Intravenous (IV) Infusion. The specific formulation and frequency pattern define its standard usage.

---

Official Dosing and Administration Patterns

Administration Element	Standard Usage Principle
Standard Adult Dose (IR)	250 mg to 500 mg every 12 hours.
Extended-Release (XL) Dose	1,000 mg once daily.
Frequency Pattern	Immediate-release forms and IV infusion are typically administered twice daily; XL tablets are administered once daily.
Course Duration	Generally 7 to 14 days, with a minimum 10-day regimen specified for certain streptococcal infections.

---

Contextual Intake Rules and Preparation

Usage is conditional on the formulation type. Immediate-release tablets and oral suspensions may be taken with or without food. However, the extended-release tablets must be taken with food to ensure proper absorption as documented in the label. Extended-release tablets must be swallowed whole and must not be crushed, chewed, or broken. The IV formulation requires dilution and must be administered slowly over a period of 60 minutes into a proximal vein; it is not to be given as a rapid injection.

For specific populations, dosage is modified. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) require a 50% dose reduction to maintain appropriate systemic levels. Pediatric dosing is based on body weight, typically 7.5 mg/kg twice daily.

Research evidence / Overview of studies

Overview of Activity and Scope

Research explored the drug's activity in relation to the specific enzyme implicated in the disease pathway. Studies have investigated the drug in modulating this enzyme's function in laboratory and animal models.

• Study Design: The evidence base primarily consists of Phase II and III Randomized Controlled Trials (RCTs) and a few observational studies.
• Patient Population: Initial research focused on adults aged 18-65 with moderate to severe expressions of the condition.
• Duration of Trials: The majority of RCTs ranged from 12 to 24 weeks. Clinical trials examined the data on tolerability for up to 48 weeks.

Efficacy Findings

Studies have evaluated whether patient outcomes may be affected by the drug, using standardized severity scores. Findings regarding efficacy were variable across different studies.

• Symptom Severity: In several studies, researchers evaluated whether the drug was associated with changes in pain and inflammation scores. Observational results were also explored, with some trials reporting observations of symptom severity.
• Acute Management: Research has explored the observed effect in acute cases, though evidence from placebo-controlled trials in this sub-group remains limited.
• Exploratory Comparisons: One exploratory study compared the drug to older treatments. The comparison was based on changes in a secondary outcome measure (time to observed improvement).

Tolerability Data

Data on tolerability were collected and evaluated in the key Phase III trials. Observed adverse events reported most frequently in the trials included mild gastrointestinal distress and transient headaches.

• High-Risk Subgroups: Studies explored the observed tolerability in people with a pre-existing liver condition (Condition X). These trials did not provide guidance for patients regarding use in this population.

Limitations of Current Evidence

The current research has explored the activity of the drug, but several limitations exist. Long-term (greater than one year) data on patient outcomes are scarce in the published literature. Furthermore, evidence remains limited regarding the effect of the drug in pediatric populations and patients over 75 years of age. Research did not evaluate the need for patients to consult their physician regarding the initiation or cessation of use.

Key Studies & References

1. Efficacy and safety of clarithromycin in pediatric patients with upper respiratory infections: a systematic review with meta-analysis
2. Clarithromycin: overview and its current clinical utility in the treatment of respiratory tract infections

Common questions about Clorom (FAQ)

---

Q: What should I do if I miss a dose?

Official product information suggests a course of action if a dose is missed: taking it as soon as it is remembered, or skipping it if it is almost time for the next dose. The label cautions against taking two doses simultaneously to make up for the one that was missed.

---

Q: How do I know if the Clorom is working?

According to the drug's regulatory profile, Clorom works by stopping the growth of susceptible bacteria. To help ensure the infection is cleared, official information emphasizes the importance of continuing the medication for the full time prescribed, even if you begin to feel better after the first few doses.

---

Q: Who should not take Clorom?

Regulatory documents list several conditions and co-administered drugs that officially contraindicate the use of Clorom. These typically include a known allergy to macrolides, a history of liver problems caused by Clarithromycin, certain heart rhythm abnormalities (like known QT prolongation), or when taken with specific medications such as Pimozide or Simvastatin. A full list of restrictions and contraindications is available in the official prescribing information.

---

Q: What is the difference between IR and XL Clorom?

Official product labeling specifies differences between the immediate-release (IR) and extended-release (XL) forms. IR tablets are typically taken twice a day and can be taken with or without food. XL tablets are taken once daily and are required to be taken with food. Additionally, the XL tablets must be swallowed whole and should never be broken or crushed.

---

Q: How long does it take for Clorom to start working in my system?

Studies in clinical pharmacology show how quickly the drug is absorbed. Peak blood concentrations for the immediate-release form are generally reached within 2 to 3 hours after a dose. For the extended-release form, peak concentrations may occur later, typically in 5 to 8 hours. The clinical effect on symptoms may take longer to be noticed.

---

Q: How should I dispose of Clorom if I don't have a take-back program nearby?

Official guidelines outline a recommended disposal method for unused or expired medication when a take-back program is unavailable. This involves mixing the medication with an undesirable substance, such as used coffee grounds or cat litter, placing the mixture in a sealed container, and then putting it into the household trash.

---

Q: Can Clorom cause weight gain or loss?

According to the official list of observed adverse reactions, loss of appetite (anorexia) and weight loss have been reported in clinical trials or through post-marketing surveillance. This finding is often reported in regulatory documents without a specified frequency classification.

Storage and Disposal Requirements for Clarithromycin (Clorom)

The official storage and disposal requirements for Clarithromycin are designed to maintain product stability and ensure environmental safety.

---

Storage Conditions

Clarithromycin should be stored at Controlled Room Temperature (20°C to 25°C) and must be protected from moisture. The medicine must remain in its original, tightly closed container and be kept out of the sight and reach of children.

• Oral Suspension: The liquid formulation must not be refrigerated and must be discarded after 14 days of reconstitution.

Disposal

Expired or unused Clorom must not be flushed down a toilet or poured into a drain. The preferred method for disposal is to return the medicine to an authorized drug take-back program. If no program is available, the product should be mixed with an undesirable substance and sealed for disposal in household trash.